||ORD SHS $0.25
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Astrazeneca Share Discussion Threads
Showing 9901 to 9922 of 9925 messages
|Read AlphaValue's note on ASTRAZENECA PLC (AZN), out this morning, by visiting hxxps://www.research-tree.com/company/GB0009895292
"AstraZeneca’s Q1 results came in behind our expectations with product sales growth of 1% to $5.6bn. Externalisation revenue (+78%) contributed $550m, leading to group sales of $6.1bn (+5%). NB All growth numbers at CER unless specific otherwise. Currency had a negative impact of 4% on group sales, which ended at 1% growth yoy. Higher-than-expected R&D spend (+11%) was offset to some extent by effective cost containment at COGS (-19%) and SG&A (-8%), culminating in reported operating profit of $1bn (+17%). Core operating..."|
|Taken some more @ £38.16 - Good value.
|Oh help what is happening to our share price.
Something is causing this|
|Nice one PHIL , weather forecast looks outstanding for the next few weeks. My flight leaves Heathrow around 6:30am on friday , connection at Madrid onto Almeria, can`t wait, peeing it down in South Bucks this morning :-)
Deutsche 'buy' tp 5600p ... reiterates|
|phil, in Espana.|
|'AstraZeneca climbs after positive asthma treatment results'
Company hopes to submit benralizumab to US and EU regulators later this year
|Very good rns today, should go higher.|
|‘Hold’ AstraZeneca for ‘cutting-edge’ drugs pipeline
Shore Capital has resumed coverage of pharmaceutical giant AstraZeneca (AZN) as the company undergoes a period of transition.
Shore Capital analyst Tara Raveendran initiated coverage of the UK drugs company with a ‘hold’ but did not set a share price target.
‘AstraZeneca is undergoing a period of transition,’ she said. ‘Its mature franchises are slowing in the face of competition and genericisation, however, it boasts a full but emerging pipeline of unique assets in existing and new therapeutic areas that are not yet contributing to the top-line.
‘While we are more positive over the medium to longer term, encouraged by management’s commitment to cutting-edge science and its exciting pipeline, lacklustre earnings and limited pipeline visibility are likely to be near-term overhangs for the stock,’ she added.
This week the company borrowed €2.2 billion in a private loan note placing on which it will pay a fixed coupons of 0.25%, 0.75% and 1.25%. Yesterday the shares added 8.5p or 0.2% to £39.36.
|Jefferies reiterates 'hold' ... cuts tp from 4200p to 3900p|
|Well monty would you just squander it on investments?|
|What a deal they receive a 2.2 billion loan virtual interest free from the EU. Wish I could lol.|
|Charles Stanley strong BUY.|
|debt is not cheap when there is deflation about.
the capital still needs to be paid back.
0.25% can be expensive when negative interest rates are common.
if it is used to cancel dearer debt then fine, it is a cash gift.|
|Wow they have got the bond paying interest 0.25% they might as well called it a free loan.
Cheaper than Wonga lol.|
|(ShareCast News) - AstraZeneca was marketing €2.2bn of debt in a three-part of deal, according to people familiar with the deal cited by Bloomberg.
Airbus Group and Royal Dutch Shell were also marketing their own bonds, the same people said, with US outfit Bunge and Spanish insurer Mapfre having also hired banks for possible sales, other people told the newswire.
Firms were keen to take advantage of the European Central Bank's decision to start purchasing corporate debt in May, with highly-rated outfits having issued approximately €65bn of securities since the ECB outlined its intentions on 10 March.
Shell was reportedly intending to sell €1.75bn-worth of bonds maturing in eight and 12 years.
For its part, aerospace giant Airbus was said to be looking for buyers for €900m on 15-year bonds at a yield of about 60 basis points above benchmark rates, less than had been initially discussed. A ten-year bond sale was also in the works.
Data released on 6 May by EPFR Global showed that in the latest week credit funds had recorded their biggest inflow in seven weeks, with the ECB's programme of corporate-quantitative easing seen as the main driver by Bank of America-Merrill Lynch's Ioannis Angelakis.|
|Astra no defense this time, turned down £55 now £39, fund managers must be kicking themselves, once bitten twice shy. Strong $ surely now is the time to strike if they were going to.|
|Pfizer $208 billion mkt cap.|
|Hope yr right Monty, nice rise.|
|Are Pfizer coming back for second bite of the cherry?. They bid £55 now Astra £39, surely with the strong $ as well, Now is the time. Easily get Astra this time.|
|£55 was the last bid, now £39, they would easily get Astra and with the strong $ its time.|
|Crazy price for Astra with the strong $ they must go for it again. Don't be short.|
|Must be bid spec monty?, did not see the bounce tbh.|